A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Recruiting
Phase 1
Interventional Study
Platinum-resistant Ovarian Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Stemline Therapeutics, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria:
* Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Key Exclusion Criteria:
* Participants with primary platinum-refractory disease.
Note: Other protocol-defined inclu…
Contacts
Stemline Trials
1-877-332-7961
cwilliams@menarinistemline.com; MEN2501_StudyTeam@menarinistemline.com
CONTACT